{"artifact":{"id":"open_question-therapeutics-974cd409","artifact_type":"open_question","entity_ids":"[\"therapeutics\"]","title":"Could pharmacological restoration of delta-catenin expression or function reverse the cognitive and synaptic deficits, and would such intervention be relevant for treating Cri-du-Chat syndrome or Alzh","quality_score":0.675,"created_by":"open_question_miner_papers","provenance_chain":"[]","content_hash":"941dc78908009846a9fb92b02e931798472eeca81d57980163c2070f5de72a13","metadata":{"status":"open","_origin":{"url":null,"type":"external","tracked_at":"2026-04-28T06:14:48.361306"},"field_tag":"therapeutics","source_id":"15380068","source_doi":"10.1016/j.cub.2004.08.065","source_kind":"paper","question_hash":"974cd4097a352a36","question_text":"Could pharmacological restoration of delta-catenin expression or function reverse the cognitive and synaptic deficits, and would such intervention be relevant for treating Cri-du-Chat syndrome or Alzheimer's disease?","importance_elo":1500,"_schema_version":1,"source_paper_id":"paper-10_1016_j_cub_2004_08_065","evidence_summary":"These data reveal a critical role for delta-catenin in brain function and may have important implications for understanding mental retardation syndromes","tractability_score":0.5,"potential_impact_score":0.85,"is_answerable_in_principle":true},"created_at":"2026-04-27T23:14:48.361392-07:00","updated_at":"2026-04-27T23:14:48.361392-07:00","version_number":4,"parent_version_id":null,"version_tag":null,"changelog":null,"is_latest":1,"lifecycle_state":"active","superseded_by":null,"deprecated_at":null,"deprecated_reason":null,"dependencies":null,"market_price":0.5,"origin_type":"external","origin_url":null,"lifecycle_changed_at":null,"citation_count":0,"embed_count":0,"derivation_count":0,"support_count":0,"contradiction_count":0,"total_usage":0.0,"usage_score":0.5,"usage_computed_at":null,"quality_status":null,"contributors":[],"answers_question_ids":null,"deprecated_reason_detail":null,"deprecated_reason_code":null,"commit_sha":null,"commit_submodule":null,"last_mutated_at":"2026-05-16T14:51:34.657673-07:00","disputed_at":null,"gap_id":null,"mission_id":null,"intrinsic_priority":null,"effective_priority":null,"artifact_id":"abdfdf6b-6b14-40a5-b999-613dc6f5e9f8","artifact_dir":null,"primary_filename":null,"accessory_filenames":null,"folder_layout_version":1,"migrated_to_folder_at":null,"hypothesis_id":null,"authorship":{"kind":"human","contributors":[{"role":"author","actor_ref":"open_question_miner_papers"}]},"epistemic_tier":"T3_provisional","created_by_agent_id":null},"outgoing_links":[],"incoming_links":[],"current_artifact_id":"open_question-therapeutics-974cd409","is_canonical":true,"supersede_chain":["open_question-therapeutics-974cd409"]}